Mammalian target of rapamycin: A new molecular target for breast cancer

Clinical Breast Cancer

Volumn 4, Issue 2, 2003, Pages 126-137

  Mita, Monica M ^a   Mita, Alain ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

CCI 779; EGFR; PI3K pathway; PTEN; Retinoblastoma; Ribosomal protein

Indexed keywords

ANTINEOPLASTIC AGENT; AP 23573; BINDING PROTEIN; CALCIUM; CHOLESTEROL; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; EVEROLIMUS; FK 506 BINDING PROTEIN; IMMUNOPHILIN; INITIATION FACTOR 4E; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P70; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RETINOBLASTOMA PROTEIN; S6 KINASE; TEMSIROLIMUS; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RETENTION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRY SKIN; ECZEMA; ENZYME ACTIVATION; ENZYME INHIBITION; FOLLICULITIS; GENE FUNCTION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; LEUKOPENIA; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MAMMAL; MITOSIS INHIBITION; MOLECULAR MECHANICS; MOUSE; MUCOSA INFLAMMATION; NAIL DISEASE; NEUTROPENIA; NONHUMAN; PROTEIN BINDING; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RASH; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SUPPRESSOR GENE; THROMBOCYTOPENIA;

EID: 0042197413     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.018     Document Type: Article

References (148)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal tranduction and tumorigenesis. Eur J Biochem 1999; 263:605-611.
3. Sherr CJ. The Pezcoller Lecture: cancer cell cycle revisited. Cancer Res 2000; 60:3689-3695.
4. Sarkaria JN, Tibbetts RS, Busby EC, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998; 58:4375-4382.
5. Keith CT, Schreiber SL. PIK-related kinase: DNA repair, recombination, and cell cycle checkpoints. Science 1995; 270:50-51.
6. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. Nat Genet 1995; 11:115-116.
7. Fry MJ. Phosphoinositide 3-kinase signaling in breast cancer: how big a role might it play? Breast Cancer Res 2001; 3:304-312.
8. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of Raf-MEK-ERK pathway by Akt. Science 1999; 286:1738-1741.
9. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286:1741-1744.
10. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989) a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975; 28:721-726.
11. Baker A, Sidorowicz A, Sehgal SN, et al. Rapamycin (AY-22,989), a new anti-fungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot 1978; 31:539-545.
12. Singh K, Sun S, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic IV. Mechanism of action. J Antibiot 1979; 32:630-645.
13. Kino R, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot 1987; 40:1249-1255.
14. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc 1990; 22:1638-1641.
15. Morris RE, Meiser BM, Wu J, et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cylosporin, and FK-506 and effect of host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23:521-524.
16. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot Tokyo) 1984; 37:1231-1237.
17. Dilling MB, Dias P, Shapiro DN. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insuline growth receptor. Cancer Res 1994; 54:903-907.
18. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996; 56: 3895-3897.
19. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells.Transplant 1995; 60:264-270.
20. Wiederrecht GJ, Sabers CJ, Brunn GJ et al. Mechanism of action of rapamycin: new insight into the regulation of G1-phase progression in eucharyotic cells. Prog Cell Cycle Res 1995; 1:53-71.
21. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin- dependent fashion and is homologous to yeast TORs. Cell 1994; 78:35-43.
22. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270:815-822.
23. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-758.
24. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994; 91:12574-12578.
25. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal from amino acid and glucose deprivation. Mol Cell Biol 2002, 22:5575-5584.
26. Gibbons JJ, Discafani C, Peterson R, et al. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc Am Assoc Cancer Res 1999; 40:301 (Abstract #2000).
27. Raymond E, Alexandre J, Depenbrock H, et al. CCI-779, a rapamycin analogue with antitumor activity: a phase I study utilizing a weekly schedule. Proc Am Soc Clin Oncol 2000; 19:187 (Abstract #728).
28. Raymond E, Alexandre J, Depenbrock H, et al. CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3k kinase pathways. A phase I study utilizing a weekly intravenous schedule. Proceedings of the 11th NCI-EORTC-AACR symposium on new drugs in cancer therapy. Clin Cancer Res 2000; 6(suppl):4549s (Abstract #414).
29. Hidalgo M, Rowinsky E, Erlichman C, et al. CCI-779, a rapamycin analogue and multifaceted inhibitor of signal transduction: a phase I study. Proc Am Soc Clin Oncol 2000; 19:187 (Abstract #726).
30. Hidalgo M, Rowinsky E, Erlichman C, et al. Phase I and pharmacological study of CCI-779, a cell cycle inhibitor. Proceedings of the 11th NCI-EORTC-AACR symposium on new drugs in cancer therapy. Clin Cancer Res 2000; 6(suppl):4548s (Abstract #413).
31. O'Reilly T, Vaxelaire J, Muller M, et al. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43:71 (Abstract #359).
32. Lane H, Schnell C, Theuer A, et a. Antiangiogenetic activity of RAD 001, an orally active anticancer agent. Proc Am Assoc Cancer Res 2002; 43:184 (Abstract #922).
33. Barbet NC, Schneider U, Helliwel SB, et al. TOR controls translation, initiation and early G1 progression in yeast. Mol Biol Cell 1996; 7:1227-1238.
34. Jefferies HB, Fumagalli S, Dennis PB, et al. Rapamycin suppress 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16:3693-3704.
35. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to rebosomes and regulators of translation. Annu Rev Biochem 1999; 68:913-963.
36. Dumont FJ, Kastner C, Iacovone F, et al. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T lymphocytes. J Pharmacol Exp Ther 1994; 268:32-41.
37. Fruman DA, Wood MA, Gjertson CK, et al. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1995; 25:563-571.
38. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253:905-909.
39. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppresive ligands. Science 1991; 251:283-287.
40. Koltin Y, Faucette L, Bergsma DJ. et al. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol 1991; 11:1718-1723.
41. Van Duyne GD, Standaert RF, Karplus PA, et al. Atomic structure of FKBp-FK506, an immunophilin-immunosuppressant complex. Science 1991; 252:839-842.
42. Thomas G, Hall MN. TOR signaling and control of control of cell growth. Curr Opin Cell Biol 1997; 9:782-787.
43. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253-262.
44. Scott PH, Brunn GJ, Kohn AD, et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1998; 95:7772-7777.
45. Nave BT, Ouwens M, Withers DJ, et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999; 344:427-431.
46. Varticovski L, Harrison-Findik D, Keeler ML, et al. Role of PI3-kinase in mitogenesis. Biochem Biophys Acta 1994; 1226:1-11.
47. Toker A, Cantley LC. Signaling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387:673-676.
48. Sekulic AH, Homme CC, Yin P, et al. A direct link between the phosphoinositide 3-kinase-Akt signalling pathway and the mammalian target of rapamycin in mitogen-stimulated and trasformed cells. Cancer Res 2000; 60:3504-3514.
49. Bellacosa A, Testa JR, Staal SP, et al. A retroviral oncogene, akt encoding a serine-threonine kinaser containing a SH2-like region. Science 1991; 254:274-277.
50. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10:262-267.
51. Hu Q, Klippel A, Muslin AJ, et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995; 268:100-102.
52. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995; 49:415-421.
53. Scheid MP, Woodgett JR. Phosphatidylinositol 3′ kinase signaling in mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6:83-99.
54. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-1396.
55. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 2000; 321:847-848.
56. Pollack M. Insulin like growth factor physiology and cancer risk. Eur J Cancer 2000; 36:1224-1228.
57. Yu H, Rohan T. Role of the insulin-like growth factor family ini cancer development and progression. J Natl Cancer Inst 2000; 92:1472-1489.
58. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 1998; 47:295-302.
59. Resnicoff M, Baserga R. The role of insulin-like growth factor-I receptor in transformation and apoptosis. Ann N Y Acad Sci 1998; 842:76-81.
60. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5:95-105.
61. Cheng JQ, Godwin AK, Bellacosa A, et al. Akt2 a putative oncogene encoding a member of a subfamily of serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992; 89:9267-9271.
62. Cheng JQ, Rugerri B, Klein WM, et al. Amplification of AKT 2 in human pancreatic cells and inhibition of Akt 2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996; 93:3636-3641.
63. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64:280-285.
64. Simoncini T, Hafezi-Moghadane A, Brazil DP, et al. Interation of oestrogen receptor with the regulatory subunit of Phosphatidyl-inositol -3-OH-kinase. Nature 2000; 407:538-341.
65. Aronica SM, Katzenellenbogen BS. Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3′, 5′-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology 1991; 128:2045-2052.
66. Pietras RJ, Arboleda J, Reese DM, et al. Her-2 throsine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435-2446.
67. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 1998; 58:627-632.
68. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/Akt -mediated activation of estrogen α: a new model for anti-estrogen resistance. J Biol Chem 2001; 276:9817-9824.
69. Degrafenried L, Friedrichs W, Fulcher L, et al. The mTOR inhibitor, CCI-779, restores tamoxifen response in breast cancer cells with high Akt activity. Proc 14th NCI-EORTC-AACR symposium on molecular targets and cancer therapeutics. Eur J Cancer 2002; S158 (Abstract #528).
70. Cui X, Zhang P, Deng W, et al. IGF-I inhibits progesterone expression in breast cancer via the PI3K/AKT/mTOR pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003; 17:575-588.
71. Steck PA, Pershouse MA, Jasser SA, et al. Idenfication of a candidate tumor supressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
72. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
73. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-67.
74. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16:2259-2264.
75. Liu W, James CD, Frederick L, et al. PTEN/MMACI mutations and EGFR amplications in glioblastomas. Cancer Res 1997; 57: 5254-5257.
76. Mills GB, Lu Y, Fang X, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenensis, prognosis, and therapy. Semin Oncol 2001; 28(suppl 16):125-141.
77. Perren A, Weng LP, Brag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155:1253-1260.
78. DeGraffenried LA, Fulcher L, Hidalgo M, Reduced PTEN expression in breast cancer cells correlates with increased sensitivity to inhibitors of the PI3K pathway. Proc Am Assoc Cancer Res 2001; 42:128 (Abstract #689).
79. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98:10314-10319.
80. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277:99-101.
81. Hara K, Yonezawa K, Kozlowski MT, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272:26457-26463.
82. Chung J, Grammer TC, Lemon KP, et al. PDGF- and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994; 370:71-75.
83. Gingras AC, Kennedy SG, O'Leary M, et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway, Genes Dev 1998; 12:502-513.
84. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277:99-101.
85. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR actions. Cell 2002; 110:177-189.
86. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-175.
87. Li BDL, Liu L, Dawson M, et al. Overexpression of eukaryotic initiation factor (eIF4E) in breast carcinoma. Cancer 1997; 79:2385-2389.
88. Li BDL, McDonald R, Nassar R, et al. Clinical outcome in stage 1 to 3 breast carcinomas and eIF4E overexpression. Ann Surg 1998; 5:756-762.
89. Barlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 2000, 60:5340-5344.
90. Couch FJ, Wang XY, Wu GJ et al. Localisation of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 1999, 59:1408-1411.
91. Pain VM. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem 1996; 236:747-771.
92. Proud CG, Denton RM. Molecular mechanism for the control of translation by insulin. Biochem J 1997; 328:329-341.
93. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998; 10:268-275.
94. Smith MR, Jaramillo M, Liu YL, et al. Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells. New Biol 1990; 2:648-654.
95. Rousseau D, Gingras AC, Pause A et al. The eIF4E-binding protein 1 and 2 are negative regulators of cell growth. Oncogene 1996; 13:2415-2420.
96. Jiang H, Coleman J, Miskimins R, et al. Expression of constitutively active 4EBP-1 enhances p27kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 2003; 3:2.
97. Mendez R, Myers MGJ, With MF, et al. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation and PHAS-I phosphorylation by insulin requires receptor substrate 1 and phosphatidyl inositol 3 kinase. Mol Cell Biol 1996; 16:5991-6001.
98. Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclic D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270:21176-21180.
99. Rousseau D, Kaspar R, Rosenwald I, et al. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 1996; 93:1065-1070.
100. Berretta L, Gingras AC, Svitin YV, et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996; 15:658-664.
101. Graves LM, Bornfeldt KE, Argast GM, et al. c-AMP -and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci U S A 1995; 92:7222-7226.
102. Lin TA, Kong X, Saltiel AR, et al. Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degration, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinase-independent pathway. J Biol Chem 1995; 270:18531-18538.
103. Dilling BD, Germain GS, Dudkin L, et al. 4E-biding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277:13907-13917.
104. Von Manteuffel S, Gingras AC, Ming XF, et al. 4E-Bp1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci U S A 1996; 93:4076-4080.
105. Brunn GJ, Fadden P, Haystead TAJ, et al. Three mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J Biol Chem 1997; 272:32547-32550.
106. Fadden P, Haystead TA, Lawrence JC Jr. Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem 1997; 272:10240-10247.
107. Herbert PT, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 2002; 277: 11591-11596.
108. Di Como CJ, Arndt KT. Nutrients, via TOR proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev 1996; 10:1904-1916.
109. Murata K, Wu J, Brautigan DL. B cell receptor-associated protein alpha 4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A. Proc Natl Acad Sci U S A 1997; 148:71-82.
110. Park IH, Bachmann R, Shirazi H, et al. Regulation of ribosomal S6 kinase 2 by mammalian target of Rapamycin. J Biol Chem 2002; 277:31423-31429.
111. Brown EJ, Beal PA, Keith CT, et al. Control of p70s6 kinase by kinase activity of FRAP in vivo. Nature 1995; 377: 441-446.
112. Burnett PE, Barrow RK, Cohen NA, et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998; 95:1432-1437.
113. Dennis PB, Pullen N, Kozma SC, et al. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol cell Biol 1996; 16:6242-6251.
114. Begum N, Ragolia L. cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rate skeletal muscle cells. J Biol Chem 1996; 271:31116-31171.
115. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-573.
116. Buckley MF, Sweeney KLE, Hamilton JA, et al. Expression and amplification of cyclin genes in breast cancer. Oncogene 1993; 8:2127-2133.
117. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclic D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995; 1: 1257-1259.
118. Grewe M, Gansauge F, Schmid RM, et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cells. Cancer Res 1999; 59:3581-3587.
119. Hashemolhosseini S, Nagamine Y, Morley SJ, et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273:14424-14429.
120. Muise-Helmericks RC. Grimes HL. Bellacosa A. et al. Cyclin D expression is controled post-transcriptionaly via a phosphatidylinositol 3-kinase/Akt dependent pathway. J Biol Chem 1998; 273: 29864-29872.
121. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-258.
122. Kawamata S, Sakaida H, Hori T, et al. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998; 91:561-569.
123. Morice WG, Wiederrecht G, Brunn GJ, et al. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268:22737-22745.
124. Luo Y, Marx SO, Kiyokawa H, et al. Rapamycin resistence tied to defective regulation of p27Kip1. Mol Cell Biol 1996; 16:6744-6751.
125. Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270: 21176-21180.
126. Mahajan PB. Modulation of transciption of rRNA genes by rapamycin. Int J Immunopharmacol 1994; 16:711-721.
127. Leicht M, Simm A, Bertsch G, et al. Okadaic acid induces cellular hypertrophy in AKR-2B fibroblasts: involvment of the p70S6 kinase in the onset of protein and rRNA synthesis. Cell Growth Differ 1996, 7:1199-1209.
128. White RJ. Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control? Trends Biochem Sci 1997; 22:77-80.
129. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27 kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997; 94:6380-6385.
130. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886-894.
131. Shi Y, Frankel A, Radvanyi LG, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55:1982-1988.
132. CCI-779 investigational brochure.
133. Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidyl-inositol-3-kinase and Akt is required for antibody-mediated effects on p27, cyclin D1 and anti-tumor action. Cancer Res 2002; 62:4132-4141.
134. Grunwald V, DeGraffenried L, Russel D, et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status status in prostate cancer cells. Cancer Res 2002; 62:6141-6145.
135. Clackson T, Metcalf CA III, Rozamus LW, et al. Regression of tumor xenographs in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc Am Assoc Cancer Res 2002; 43: (Abstract #LB 95).
136. Fourouzesh B, Buckner J, Ajei A, et al. Phase I, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies. Proceedings of the 13th EORTC-NCI-AACR symposium. Eur J Cancer 2002; 38(suppl 7):S54 (Abstract #168).
137. Chan S, Johnston S, Scheulen ME, et al. First report of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc Am Soc Clin Oncol 2002; 21:44a (Abstract #175).
138. Chan S, Johnston S, Scheulen ME, et al. Phase II safety and activity trial of two levels of CCI-779 in women with previously treated locally advanced or metastatic cancer-interim report. Breast Cancer Res Treat 2002; 76(suppl 1):S132 (Abstract #526).
139. Atkins BM, Hidalgo M, Atadler W, et al. A randomised double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2002; 21:10a (Abstract #36).
140. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs; a pharmacodynamic approach. Ther Drug Monit 1998; 20:459-463.
141. Peralba JM, de Graffenriend L, Fulcher L, et al. Pharmacodynamic evaluation of the rapamycin ester CCI-779. Proc Am Assoc Cancer Res 2002; 43:1000 (Abstract #4961).
142. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 1281-1287.
143. Seymour L. The design of clinical trials for new molecularly targeted compounds: progress an new initiatives. Curr Pharm Des 2002; 8:2279-2284.
144. Adjei AA, Erlichman C, Davis JN, et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000;60:1871-1877.
145. Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000; 19:3a (Abstract #5E).
146. Betensky RA, Louis DN, Carncross JG, et al. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20:2495-2499.
147. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54:815-824.
148. Sausville EA, Zaharevitz D, Gussio R, et al. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Ther 1999; 82:285-292.